Navigation Links
Stem Cell Innovations' C3A Human Liver Cell Line is Capable of Producing Biosimilar Serum Proteins for Follow-On Biologics

Blood clotting proteins factor 8 and 9 are first target indications

HOUSTON, Feb. 24 /PRNewswire-FirstCall/ -- Stem Cell Innovations' (Pink Sheets: SCLL) liver assist device program has additional application in the production of biosimilar and novel proteins. "Many of the commercially important therapeutic proteins are liver products and comprise a multibillion dollar market in the US," said James H. Kelly, CEO of SCLL. "Albumin, the clotting factors and alpha-1-antitrypsin are all produced naturally in the liver. Our C3A cell line produces each of these proteins at levels comparable to the natural liver cell. We already have the capability for large scale culture of the C3A cell line and expect that our PluriCell(TM) derived hepatocytes will have similar production capabilities. In addition, the C3A line provides an excellent host for the production of recombinant proteins due to the liver's massive synthetic capability."

In a sign that major pharmaceutical companies are becoming more aggressive about the biosimilar business, Merck is buying Insmed's portfolio of follow-on biologics for $130 million in cash. "We are exploring ways to fund our activities in this area through a spin out or an acquisition," said Kelly.

About Stem Cell Innovations, Inc.

SCLL is a cell biology company based in Houston, TX. The Company's ACTIVTox system is a human liver based model for high throughput toxicity testing. Stem Cell Innovations' proprietary, human pluripotent stem cells, known as PluriCells, have the potential to aid in drug discovery, toxicology, and cell therapy.

Additional information is available at and at

ACTIVTox and PluriCells are Trademarks of Stem Cell Innovations, Inc.

Forward-Looking Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects," "intends," "believes," "may," "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.

SOURCE Stem Cell Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Inverness Medical Innovations Announces Fourth Quarter 2008 Results
2. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET February 18, 2009 to Discuss Fourth Quarter 2008 Results
3. James Roosevelt, Jr. Joins Inverness Medical Innovations Board of Directors
4. Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend
5. Inverness Medical Innovations to Present at the 2009 UBS Global Healthcare Services Conference on February 10, 2009
6. Young Innovations, Inc. Provides Fourth Quarter Conference Call Details
7. Can payment and other innovations improve the quality and value of health care?
8. Stem Cell Innovations, Inc., Files New Patent Application Regarding Pluripotent Stem Cell Production
9. HC Innovations Expands Management Team, Adding Vice President of Human Resources
10. Pharos Innovations Strengthens Leadership Team, Informatics Program
11. Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also think ... during the Black Friday and Cyber Monday massage chair sales to receive ... high and low to find the best massage chair deals, they can see all ...
(Date:11/26/2015)... ... 2015 , ... Somu Sivaramakrishnan announced today that he joined ... offers travelers, value and care based Travel Services, including exclusive pricing on a ... cabin upgrades and special amenities such as, shore excursions, discounted fares, travel gifts ...
(Date:11/26/2015)... NE (PRWEB) , ... November 26, 2015 , ... Jobs ... searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical Group ... during the month of October 2015 among those searching for healthcare jobs through the ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., the first ... annual Employee Benefits Conference. The Employee Benefits Conference was hosted by the International ... November 11th, 2015. The conference was held at the Hawaii Convention Center in ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology: